Nl-101, the world's first candidate compound with dual targets, signed a data sharing agreement between Chinese, British and US companies

Source: Hangzhou Minsheng Pharmaceutical Co., Ltd 2013-1-16 nl-101 is a new chemical entity originally developed by Northlake biopharmaceutical Co., Ltd with dual functions of traditional cytotoxic effect and modern molecular targeting effect In July 2011, Hangzhou Minsheng Pharmaceutical Co., Ltd obtained the patent right, R & D, production and sales right of the product in China After a year, the research group of Hangzhou Minsheng Pharmaceutical Co., Ltd successfully solved the problems of raw material synthesis and impurity separation of nl-101 In November 2012, Norske biopharmaceutical Co., Ltd signed a strategic cooperation agreement with Monti Pharmaceutical Co., Ltd of the United Kingdom, which transferred the patent rights, R & D, production and sales rights of nl-101 in other regions except China to Monti Pharmaceutical Co., Ltd of the United Kingdom for us $84.5 million 2012 11 In June, Hangzhou Minsheng Pharmaceutical Co., Ltd signed a data sharing agreement with Mengdi Pharmaceutical Co., Ltd and Norske biopharmaceutical Co., Ltd of the United Kingdom It was agreed that the three companies would inform each other of their own data and technology of the product, as well as their future research and development plans, test arrangements, test results and other information, and form regular exchanges Mechanism, in order to fully integrate and utilize the advantages of three resources to accelerate the research and development process of nl-101 The data sharing mode of the three-party company has creatively turned potential competitors in different regions of the same product into strategic partners It is a new mode in the history of new drug research and development, which can be called the original "people's livelihood mode"